LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset - HMS LINCS Database

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)

Download: Excel (XLSX), Comma-separated (CSV)

<<<<

Select the entities to show:

Small molecules	Cells

|<
<<
Previous
Page 33 of 483
Next
>>
>
801 to 825 of 12072 records
per page:

Cell	Small Molecule	Small Mol Concentration	Small Mol Conc Unit	LJP Library Plate	Replicate	Assay Well	Timepoint	Timepoint Unit	Total Cell Count Before Treatment	Total Cell Count After Treatment	Total Control Cell Count	Relative Cell Count	Relative Growth Rate After Treatment
BT-20	CP466722	0.37	uM	LJP5	3	I10	72	hr	1334	4100	3970	1.0325	1.0490
BT-20	Crizotinib	0.37	uM	LJP5	1	A22	72	hr	1334	3331	3970	0.8389	0.7573
BT-20	Crizotinib	0.37	uM	LJP5	2	A22	72	hr	1334	3419	3970	0.8610	0.7906
BT-20	Crizotinib	0.37	uM	LJP5	3	A22	72	hr	1334	3538	3970	0.8910	0.8358
BT-20	Momelotinib	0.37	uM	LJP5	1	P10	72	hr	1334	3534	3970	0.8900	0.8343
BT-20	Momelotinib	0.37	uM	LJP5	2	P10	72	hr	1334	3631	3970	0.9144	0.8711
BT-20	Momelotinib	0.37	uM	LJP5	3	P10	72	hr	1334	3812	3970	0.9600	0.9397
BT-20	Dasatinib	0.37	uM	LJP5	1	D04	72	hr	1334	1566	3970	0.3944	0.0877
BT-20	Dasatinib	0.37	uM	LJP5	2	D04	72	hr	1334	1511	3970	0.3805	0.0669
BT-20	Dasatinib	0.37	uM	LJP5	3	D04	72	hr	1334	1713	3970	0.4314	0.1435
BT-20	Dasatinib	0.37	uM	LJP6	1	I04	72	hr	1334	2058	3970	0.5183	0.2744
BT-20	Dasatinib	0.37	uM	LJP6	2	I04	72	hr	1334	1800	3970	0.4533	0.1765
BT-20	Dasatinib	0.37	uM	LJP6	3	I04	72	hr	1334	1461	3970	0.3679	0.0479
BT-20	Dovitinib	0.37	uM	LJP5	1	E22	72	hr	1334	2461	3970	0.6198	0.4273
BT-20	Dovitinib	0.37	uM	LJP5	2	E22	72	hr	1334	2399	3970	0.6041	0.4037
BT-20	Dovitinib	0.37	uM	LJP5	3	E22	72	hr	1334	2789	3970	0.7024	0.5517
BT-20	Enzastaurin	0.37	uM	LJP5	1	D16	72	hr	1334	3778	3970	0.9514	0.9268
BT-20	Enzastaurin	0.37	uM	LJP5	2	D16	72	hr	1334	3886	3970	0.9786	0.9678
BT-20	Enzastaurin	0.37	uM	LJP5	3	D16	72	hr	1334	4689	3970	1.1808	1.2724
BT-20	Erlotinib	0.37	uM	LJP5	1	M22	72	hr	1334	3781	3970	0.9522	0.9280
BT-20	Erlotinib	0.37	uM	LJP5	2	M22	72	hr	1334	3995	3970	1.0061	1.0091
BT-20	Erlotinib	0.37	uM	LJP5	3	M22	72	hr	1334	4108	3970	1.0345	1.0520
BT-20	Foretinib	0.37	uM	LJP5	1	H10	72	hr	1334	1385	3970	0.3488	0.0191
BT-20	Foretinib	0.37	uM	LJP5	2	H10	72	hr	1334	1392	3970	0.3506	0.0217
BT-20	Foretinib	0.37	uM	LJP5	3	H10	72	hr	1334	1328	3970	0.3344	-0.0025

|<
<<
Previous
Page 33 of 483
Next
>>
>
801 to 825 of 12072 records
per page:

HMS LINCS Project

LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)